Intravenous CERA maintains stable haemoglobin levels in patients on dialysis previously treated with darbepoetin alfa: results from STRIATA, a randomized phase III …
B Canaud, G Mingardi, J Braun, P Aljama… - Nephrology Dialysis …, 2008 - academic.oup.com
Background. Extending the administration interval of erythropoiesis-stimulating agents
(ESAs) represents an opportunity to improve the efficiency of anaemia management in …
(ESAs) represents an opportunity to improve the efficiency of anaemia management in …
[HTML][HTML] Iron-refractory iron deficiency anemia: new molecular mechanisms
Y Cui, Q Wu, Y Zhou - Kidney international, 2009 - Elsevier
Iron deficiency anemia is a common complication in end-stage renal disease (ESRD) and
impairs the therapeutic efficacy of recombinant erythropoietin. Oral or parental iron …
impairs the therapeutic efficacy of recombinant erythropoietin. Oral or parental iron …
Medicare's payment strategy for end-stage renal disease now embraces bundled payment and pay-for-performance to cut costs
Since 1973 Medicare has provided health insurance coverage to all people who have been
diagnosed with end-stage renal disease, or kidney failure. In this article we trace the history …
diagnosed with end-stage renal disease, or kidney failure. In this article we trace the history …
Hemoglobin variability in nondialysis chronic kidney disease: examining the association with mortality
NC Boudville, O Djurdjev, IC Macdougall… - Clinical Journal of the …, 2009 - journals.lww.com
Background and objectives: Anemia and hemoglobin (Hb) variability are associated with
mortality in hemodialysis patients who are on erythropoiesis-stimulating agents (ESA). Our …
mortality in hemodialysis patients who are on erythropoiesis-stimulating agents (ESA). Our …
Naturally occurring higher hemoglobin concentration does not increase mortality among hemodialysis patients
DA Goodkin, DS Fuller, BM Robinson… - Journal of the …, 2011 - journals.lww.com
A small percentage of hemodialysis patients maintain higher hemoglobin concentrations
without transfusion or erythropoietic therapy. Because uncertainty exists regarding the …
without transfusion or erythropoietic therapy. Because uncertainty exists regarding the …
What is causing the mortality in treating the anemia of chronic kidney disease: erythropoietin dose or hemoglobin level?
AK Singh - Current opinion in nephrology and hypertension, 2010 - journals.lww.com
After 20 years of ESA use, is it plausible that ESAs could be toxic? How does one reconcile
conflicting observational data with a hypothesis that postulates ESA toxicity? Does the …
conflicting observational data with a hypothesis that postulates ESA toxicity? Does the …
Evidence and implications of haemoglobin cycling in anaemia management
S Fishbane, JS Berns - Nephrology Dialysis Transplantation, 2007 - academic.oup.com
Treatment with erythropoietic-stimulating agents (ESA) has been a major advance for
improving the lives of patients with chronic kidney disease (CKD). Treatment, however …
improving the lives of patients with chronic kidney disease (CKD). Treatment, however …
Effect of epoetin alfa dose changes on hemoglobin and mortality in hemodialysis patients with hemoglobin levels persistently below 11 g/dL
BD Bradbury, MD Danese, M Gleeson… - Clinical Journal of the …, 2009 - journals.lww.com
Effect of Epoetin Alfa Dose Changes on Hemoglobin and Mortal... : Clinical Journal of the
American Society of Nephrology Effect of Epoetin Alfa Dose Changes on Hemoglobin and …
American Society of Nephrology Effect of Epoetin Alfa Dose Changes on Hemoglobin and …
[HTML][HTML] Impact of intravenous iron on oxidative stress and mitochondrial function in experimental chronic kidney disease
F Nuhu, AM Seymour, S Bhandari - Antioxidants, 2019 - mdpi.com
Background: Mitochondrial dysfunction is observed in chronic kidney disease (CKD). Iron
deficiency anaemia (IDA), a common complication in CKD, is associated with poor clinical …
deficiency anaemia (IDA), a common complication in CKD, is associated with poor clinical …
Increased mortality in haemodialysis patients administered high doses of erythropoiesis-stimulating agents: a propensity score-matched analysis
R Pérez-García, J Varas, A Cives… - Nephrology Dialysis …, 2018 - academic.oup.com
Abstract Background Erythropoiesis-stimulating agents (ESAs) are widely used to treat
anaemia in patients with chronic kidney disease. The issue of ESA safety has been raised in …
anaemia in patients with chronic kidney disease. The issue of ESA safety has been raised in …